Skip to main content

Copiktra

Generic name: duvelisibDOO-ve-LIS-ib ]
Drug class: PI3K inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on May 8, 2024.

What is Copiktra?

Copiktra is a prescription medicine used to treat adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

Copiktra is given after at least two other cancer treatments did not work or have stopped working.

It is not known if Copiktra is safe and effective in children less than 18 years of age.

Warnings

Copiktra can cause serious or fatal side effects, including serious infections, severe diarrhea, or a life-threatening skin rash.

Call your doctor right away if you have symptoms such as:

Before taking this medicine

To make sure Copiktra is safe for you, tell your doctor if you have ever had:

Both men and women using this medicine should use effective birth control to prevent pregnancy. Duvelisib can harm an unborn baby or cause birth defects if the mother or father is using this medicine.

Keep using birth control for at least 1 month after your last dose. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Copiktra.

It is not safe to breast-feed a baby while you are using duvelisib. Also do not breast-feed for at least 1 month after your last dose.

How should I take Copiktra?

Take Copiktra exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.

You may take Copiktra with or without food.

Swallow the capsule whole and do not crush, chew, break, or open it.

Copiktra can cause severe diarrhea, which can be life-threatening. You may need to take medication to prevent or quickly treat diarrhea.

You may be given other medications to help prevent serious side effects. Keep using these medicines for as long as your doctor has prescribed.

Your doctor will need to check your progress on a regular basis, and you will need frequent medical tests. Your cancer treatments may be delayed based on the results.

Store capsules in the blister pack at room temperature, away from moisture and heat.

What happens if I miss a dose?

Take the medicine as soon as you can, but skip the missed dose if you are more than 6 hours late for the dose. Do not take two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What to avoid

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Copiktra side effects

Get emergency medical help if you have signs of an allergic reaction to Copiktra (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Call your doctor at once if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Copiktra side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Copiktra?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may interact with duvelisib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Imbruvica, Venclexta, rituximab, cyclophosphamide, Rituxan, Calquence

Frequently asked questions

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Copiktra only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.